Work detail

Social and Medical Costs of Dupuytren's Desease

Author: Bc. Jakub Losenický
Year: 2014 - summer
Leaders: PhDr. Jana Votápková
Consultants:
Work type: Bachelors
Language: English
Pages: 75
Awards and prizes: B.A. with distinction from the Dean of the Faculty of Social Sciences for an excellent state-final examination performance and for an extraordinarily good bachelors diploma thesis.
Link: https://is.cuni.cz/webapps/zzp/detail/138405/
Abstract: The thesis investigates the relative cost-effectiveness of two treatment methods of Dupuytren's disease
(DD) - surgical fasciectomy and injectable collagenase - and assesses the impact of the two health
technologies on the budget of the Czech Republic. For this purpose, cost-minimization analysis (CMA)
and budget impact analysis (BIA) are employed and, importantly, both social and medical costs are
taken into consideration. Concerning the CMA, different patients are modelled with respect to personal
characteristics such as occupation, type of work (manual, non-manual) and income. In the BIA, data on
DD occurrence in the Czech Republic from the National Register of Hospitalised Patients (NRHOSP)
are analysed. We found that collagenase is a cost-minimizing treatment for a big majority of employees
and manually working SMEs. On the other hand, collagenase turned out to be more expensive than
fasciectomy for most of the non-manual SMEs. All things considered, collagenase appeared to be
cheaper for most of the model patients. We also discovered that if all the patients in the dataset were
treated with collagenase, the Czech state budget would annually save 1,685,452 CZK. The average
annual costs of fasciectomy and collagenase were 41,334,049 CZK and 39,648,597 CZK, respectively

Partners

ČSOB
Deloitte
McKinsey & Company

Sponsors

CRIF